[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fkyYldDiN-Cf5HNkJQy4scE3w8THuDMY93fE6QQSvC0s":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":69,"rows":76},"University Hospital Schleswig-Holstein",[4],159,false,24,6,47211,13,121,[14,16,19,21,24,27,29,31],{"name":15,"count":9},"Hypothermia",{"name":17,"count":18},"Pain",5,{"name":20,"count":18},"Renal Transplantation",{"name":22,"count":23},"Hemodynamics",4,{"name":25,"count":26},"Lung Cancer",3,{"name":28,"count":26},"Parkinson Disease",{"name":30,"count":26},"Atopic Dermatitis",{"name":32,"count":26},"Psoriasis",[34,39,44,49,54,59,64],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT07244744","Tilrdakizumab Almirall","2024-12-31","Tildrakizumab",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06097533","Improvement of Quality of Life by Cannabinoids in Oncologic Patients","2026-11-30","Cannabisextrakt Avextra 10\u002F10 Lösung",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06488625","Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients With Mild to Moderately Active Ulcerative Colitis","2027-10","Low-Dose CICR-NAM",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT07444801","Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact","2027-10-31","tralokinumab",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT07235904","Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis","2028-03","Mirikizumab",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT07286747","Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)","2028-05-01","controlled-ileal-release nicotinic acid as multiple dose 100 mg\u002Fday",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT05928169","Determinants of Chronic Inflammatory Skin Disease Trajectories","2032-04-30","Topical and systemic drugs",[70,71,72,73,74,75],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[77,103,121,146,164,182,200,224,248,266,284,306,333,354,379,401,426,451,502,524,546,568,590,612,634,656,678,700,722,744,766,784,809,841,859,877,895,913,931,949,967,985,1010,1036,1054,1080,1098,1124,1142,1167,1198,1223,1250,1268,1293,1311,1336,1362,1380,1404,1422,1448,1474,1501,1519,1545,1571,1595,1621,1639,1657,1675,1702,1720,1746],{"intervention":58,"totalTrials":78,"cells":79},1,{"EARLY_PHASE1":80,"PHASE1":83,"PHASE2":85,"PHASE3":87,"PHASE4":89,"NA":101},{"trials":81,"activeCount":82},[],0,{"trials":84,"activeCount":82},[],{"trials":86,"activeCount":82},[],{"trials":88,"activeCount":82},[],{"trials":90,"activeCount":78,"soonestReadout":57},[91],{"nctId":55,"briefTitle":56,"status":92,"phases":93,"primaryCompletion":57,"completion":94,"start":95,"enrollment":96,"conditions":97,"interventions":99},"RECRUITING",[74],"2028-10","2025-12-05",300,[98],"Ulcerative Colitis (UC)",[58,100],"Azathioprine",{"trials":102,"activeCount":82},[],{"intervention":100,"totalTrials":78,"cells":104},{"EARLY_PHASE1":105,"PHASE1":107,"PHASE2":109,"PHASE3":111,"PHASE4":113,"NA":119},{"trials":106,"activeCount":82},[],{"trials":108,"activeCount":82},[],{"trials":110,"activeCount":82},[],{"trials":112,"activeCount":82},[],{"trials":114,"activeCount":78,"soonestReadout":57},[115],{"nctId":55,"briefTitle":56,"status":92,"phases":116,"primaryCompletion":57,"completion":94,"start":95,"enrollment":96,"conditions":117,"interventions":118},[74],[98],[58,100],{"trials":120,"activeCount":82},[],{"intervention":48,"totalTrials":78,"cells":122},{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":142,"NA":144},{"trials":124,"activeCount":82},[],{"trials":126,"activeCount":82},[],{"trials":128,"activeCount":82},[],{"trials":130,"activeCount":78,"soonestReadout":47},[131],{"nctId":45,"briefTitle":46,"status":92,"phases":132,"primaryCompletion":47,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":138},[72,73],"2027-12","2024-09-12",459,[137],"Ulcerative Colitis, Unspecified",[48,139,140,141],"High-Dose CICR-NAM","0 g\u002Fd CICR-NAM","Open-Label",{"trials":143,"activeCount":82},[],{"trials":145,"activeCount":82},[],{"intervention":139,"totalTrials":78,"cells":147},{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":160,"NA":162},{"trials":149,"activeCount":82},[],{"trials":151,"activeCount":82},[],{"trials":153,"activeCount":82},[],{"trials":155,"activeCount":78,"soonestReadout":47},[156],{"nctId":45,"briefTitle":46,"status":92,"phases":157,"primaryCompletion":47,"completion":133,"start":134,"enrollment":135,"conditions":158,"interventions":159},[72,73],[137],[48,139,140,141],{"trials":161,"activeCount":82},[],{"trials":163,"activeCount":82},[],{"intervention":140,"totalTrials":78,"cells":165},{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":172,"PHASE4":178,"NA":180},{"trials":167,"activeCount":82},[],{"trials":169,"activeCount":82},[],{"trials":171,"activeCount":82},[],{"trials":173,"activeCount":78,"soonestReadout":47},[174],{"nctId":45,"briefTitle":46,"status":92,"phases":175,"primaryCompletion":47,"completion":133,"start":134,"enrollment":135,"conditions":176,"interventions":177},[72,73],[137],[48,139,140,141],{"trials":179,"activeCount":82},[],{"trials":181,"activeCount":82},[],{"intervention":141,"totalTrials":78,"cells":183},{"EARLY_PHASE1":184,"PHASE1":186,"PHASE2":188,"PHASE3":190,"PHASE4":196,"NA":198},{"trials":185,"activeCount":82},[],{"trials":187,"activeCount":82},[],{"trials":189,"activeCount":82},[],{"trials":191,"activeCount":78,"soonestReadout":47},[192],{"nctId":45,"briefTitle":46,"status":92,"phases":193,"primaryCompletion":47,"completion":133,"start":134,"enrollment":135,"conditions":194,"interventions":195},[72,73],[137],[48,139,140,141],{"trials":197,"activeCount":82},[],{"trials":199,"activeCount":82},[],{"intervention":43,"totalTrials":78,"cells":201},{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":206,"PHASE3":218,"PHASE4":220,"NA":222},{"trials":203,"activeCount":82},[],{"trials":205,"activeCount":82},[],{"trials":207,"activeCount":78,"soonestReadout":42},[208],{"nctId":40,"briefTitle":41,"status":92,"phases":209,"primaryCompletion":42,"completion":42,"start":210,"enrollment":211,"conditions":212,"interventions":217},[72],"2024-04-08",170,[213,214,215,216],"Medical Oncology","Palliative Care","Quality of Life","Cannabinoids",[43],{"trials":219,"activeCount":82},[],{"trials":221,"activeCount":82},[],{"trials":223,"activeCount":82},[],{"intervention":63,"totalTrials":78,"cells":225},{"EARLY_PHASE1":226,"PHASE1":228,"PHASE2":230,"PHASE3":242,"PHASE4":244,"NA":246},{"trials":227,"activeCount":82},[],{"trials":229,"activeCount":82},[],{"trials":231,"activeCount":78,"soonestReadout":62},[232],{"nctId":60,"briefTitle":61,"status":92,"phases":233,"primaryCompletion":62,"completion":234,"start":235,"enrollment":236,"conditions":237,"interventions":239},[72],"2028-12-31","2026-03-03",390,[238],"Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)",[63,240,241],"controlled-ileal-release nicotinic acid as multiple dose 200 mg\u002Fday","controlled-ileal-release nicotinic acid as multiple dose placebo",{"trials":243,"activeCount":82},[],{"trials":245,"activeCount":82},[],{"trials":247,"activeCount":82},[],{"intervention":240,"totalTrials":78,"cells":249},{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":260,"PHASE4":262,"NA":264},{"trials":251,"activeCount":82},[],{"trials":253,"activeCount":82},[],{"trials":255,"activeCount":78,"soonestReadout":62},[256],{"nctId":60,"briefTitle":61,"status":92,"phases":257,"primaryCompletion":62,"completion":234,"start":235,"enrollment":236,"conditions":258,"interventions":259},[72],[238],[63,240,241],{"trials":261,"activeCount":82},[],{"trials":263,"activeCount":82},[],{"trials":265,"activeCount":82},[],{"intervention":241,"totalTrials":78,"cells":267},{"EARLY_PHASE1":268,"PHASE1":270,"PHASE2":272,"PHASE3":278,"PHASE4":280,"NA":282},{"trials":269,"activeCount":82},[],{"trials":271,"activeCount":82},[],{"trials":273,"activeCount":78,"soonestReadout":62},[274],{"nctId":60,"briefTitle":61,"status":92,"phases":275,"primaryCompletion":62,"completion":234,"start":235,"enrollment":236,"conditions":276,"interventions":277},[72],[238],[63,240,241],{"trials":279,"activeCount":82},[],{"trials":281,"activeCount":82},[],{"trials":283,"activeCount":82},[],{"intervention":53,"totalTrials":78,"cells":285},{"EARLY_PHASE1":286,"PHASE1":288,"PHASE2":290,"PHASE3":292,"PHASE4":294,"NA":296},{"trials":287,"activeCount":82},[],{"trials":289,"activeCount":82},[],{"trials":291,"activeCount":82},[],{"trials":293,"activeCount":82},[],{"trials":295,"activeCount":82},[],{"trials":297,"activeCount":78,"soonestReadout":52},[298],{"nctId":50,"briefTitle":51,"status":92,"phases":299,"primaryCompletion":52,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":305},[],"2028-06-30","2025-10-20",30,[304],"Atopic Dermatitis (Moderate-to-severe) Involving the Genital Region",[53],{"intervention":68,"totalTrials":78,"cells":307},{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":314,"PHASE4":316,"NA":318},{"trials":309,"activeCount":82},[],{"trials":311,"activeCount":82},[],{"trials":313,"activeCount":82},[],{"trials":315,"activeCount":82},[],{"trials":317,"activeCount":82},[],{"trials":319,"activeCount":78,"soonestReadout":67},[320],{"nctId":65,"briefTitle":66,"status":92,"phases":321,"primaryCompletion":67,"completion":322,"start":323,"enrollment":324,"conditions":325,"interventions":332},[],"2032-12-31","2023-05-01",1000,[30,32,326,327,328,329,330,331],"Lichen Planus","Alopecia Areata","Hidradenitis Suppurativa","Prurigo Nodularis","Cutaneous Lupus","Rosacea",[68],{"intervention":38,"totalTrials":78,"cells":334},{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":343,"NA":345},{"trials":336,"activeCount":82},[],{"trials":338,"activeCount":82},[],{"trials":340,"activeCount":82},[],{"trials":342,"activeCount":82},[],{"trials":344,"activeCount":82},[],{"trials":346,"activeCount":78,"soonestReadout":37},[347],{"nctId":35,"briefTitle":36,"status":348,"phases":349,"primaryCompletion":37,"completion":350,"start":351,"enrollment":26,"conditions":352,"interventions":353},"ACTIVE_NOT_RECRUITING",[],"2026-04-30","2023-06-27",[32],[38],{"intervention":355,"totalTrials":78,"cells":356},"sirolimus, mycophenolat mofetil, fluvastatin",{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":365,"NA":377},{"trials":358,"activeCount":82},[],{"trials":360,"activeCount":82},[],{"trials":362,"activeCount":82},[],{"trials":364,"activeCount":82},[],{"trials":366,"activeCount":82},[367],{"nctId":368,"briefTitle":369,"status":370,"phases":371,"completion":372,"start":373,"enrollment":374,"conditions":375,"interventions":376},"NCT00223028","Investigation of the Steady State Pharmacokinetics of Sirolimus, Mycophenolat Mofetil and Fluvastatin After Renal Transplantation","COMPLETED",[74],"2005-07","2005-04",15,[20],[355],{"trials":378,"activeCount":82},[],{"intervention":380,"totalTrials":78,"cells":381},"Fluvastatin, Tacrolimus, Mycophenolat Mofetil",{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":388,"PHASE4":390,"NA":399},{"trials":383,"activeCount":82},[],{"trials":385,"activeCount":82},[],{"trials":387,"activeCount":82},[],{"trials":389,"activeCount":82},[],{"trials":391,"activeCount":82},[392],{"nctId":393,"briefTitle":394,"status":370,"phases":395,"completion":373,"start":396,"enrollment":374,"conditions":397,"interventions":398},"NCT00223015","Investigation of the Steady State Pharmacokinetics of Tacrolimus, Mycophenolate Mofetil and Fluvastatin After Renal Transplantation",[74],"2004-05",[20],[380],{"trials":400,"activeCount":82},[],{"intervention":402,"totalTrials":78,"cells":403},"tapentadol, oxycodone",{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":408,"PHASE3":410,"PHASE4":412,"NA":424},{"trials":405,"activeCount":82},[],{"trials":407,"activeCount":82},[],{"trials":409,"activeCount":82},[],{"trials":411,"activeCount":82},[],{"trials":413,"activeCount":82},[414],{"nctId":415,"briefTitle":416,"status":417,"phases":418,"primaryCompletion":419,"completion":419,"start":420,"enrollment":26,"conditions":421,"interventions":423},"NCT01458015","Tapentadol Versus Oxycodone - a Mechanism-based Treatment Approach in Neuropathic Pain","TERMINATED",[74],"2013-11","2011-10",[422],"Peripheral Neuropathy",[402],{"trials":425,"activeCount":82},[],{"intervention":427,"totalTrials":78,"cells":428},"Sevoflurane",{"EARLY_PHASE1":429,"PHASE1":431,"PHASE2":433,"PHASE3":435,"PHASE4":437,"NA":449},{"trials":430,"activeCount":82},[],{"trials":432,"activeCount":82},[],{"trials":434,"activeCount":82},[],{"trials":436,"activeCount":82},[],{"trials":438,"activeCount":82},[439],{"nctId":440,"briefTitle":441,"status":370,"phases":442,"completion":443,"start":444,"enrollment":445,"conditions":446,"interventions":448},"NCT00569816","Continuous Versus Repetitive Sevoflurane Administration for Preconditioning",[74],"2007-05","2005-01",50,[447],"Myocardial Injury",[427],{"trials":450,"activeCount":82},[],{"intervention":452,"totalTrials":453,"cells":454},"cyclophosphamide",2,{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":461,"PHASE4":498,"NA":500},{"trials":456,"activeCount":82},[],{"trials":458,"activeCount":82},[],{"trials":460,"activeCount":82},[],{"trials":462,"activeCount":82},[463,486],{"nctId":464,"briefTitle":465,"status":370,"phases":466,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":470,"interventions":472},"NCT00430118","Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia",[73],"2012-01","2000-07",4559,[471],"Leukemia",[473,452,474,475,476,477,478,479,480,481,482,483,484,485],"asparaginase","cytarabine","daunorubicin hydrochloride","dexamethasone","doxorubicin hydrochloride","etoposide","ifosfamide","mercaptopurine","methotrexate","prednisone","thioguanine","vincristine sulfate","vindesine",{"nctId":487,"briefTitle":488,"status":370,"phases":489,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":493,"interventions":494},"NCT01117441","International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia",[73],"2021-12-31","2010-06",6136,[471],[495,452,474,475,476,477,478,479,480,481,482,483,484,485,496,497],"PEG-L-asparaginase","daunoxome","fludarabine",{"trials":499,"activeCount":82},[],{"trials":501,"activeCount":82},[],{"intervention":474,"totalTrials":453,"cells":503},{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":510,"PHASE4":520,"NA":522},{"trials":505,"activeCount":82},[],{"trials":507,"activeCount":82},[],{"trials":509,"activeCount":82},[],{"trials":511,"activeCount":82},[512,516],{"nctId":464,"briefTitle":465,"status":370,"phases":513,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":514,"interventions":515},[73],[471],[473,452,474,475,476,477,478,479,480,481,482,483,484,485],{"nctId":487,"briefTitle":488,"status":370,"phases":517,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":518,"interventions":519},[73],[471],[495,452,474,475,476,477,478,479,480,481,482,483,484,485,496,497],{"trials":521,"activeCount":82},[],{"trials":523,"activeCount":82},[],{"intervention":475,"totalTrials":453,"cells":525},{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":532,"PHASE4":542,"NA":544},{"trials":527,"activeCount":82},[],{"trials":529,"activeCount":82},[],{"trials":531,"activeCount":82},[],{"trials":533,"activeCount":82},[534,538],{"nctId":464,"briefTitle":465,"status":370,"phases":535,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":536,"interventions":537},[73],[471],[473,452,474,475,476,477,478,479,480,481,482,483,484,485],{"nctId":487,"briefTitle":488,"status":370,"phases":539,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":540,"interventions":541},[73],[471],[495,452,474,475,476,477,478,479,480,481,482,483,484,485,496,497],{"trials":543,"activeCount":82},[],{"trials":545,"activeCount":82},[],{"intervention":476,"totalTrials":453,"cells":547},{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":554,"PHASE4":564,"NA":566},{"trials":549,"activeCount":82},[],{"trials":551,"activeCount":82},[],{"trials":553,"activeCount":82},[],{"trials":555,"activeCount":82},[556,560],{"nctId":464,"briefTitle":465,"status":370,"phases":557,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":558,"interventions":559},[73],[471],[473,452,474,475,476,477,478,479,480,481,482,483,484,485],{"nctId":487,"briefTitle":488,"status":370,"phases":561,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":562,"interventions":563},[73],[471],[495,452,474,475,476,477,478,479,480,481,482,483,484,485,496,497],{"trials":565,"activeCount":82},[],{"trials":567,"activeCount":82},[],{"intervention":477,"totalTrials":453,"cells":569},{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":576,"PHASE4":586,"NA":588},{"trials":571,"activeCount":82},[],{"trials":573,"activeCount":82},[],{"trials":575,"activeCount":82},[],{"trials":577,"activeCount":82},[578,582],{"nctId":464,"briefTitle":465,"status":370,"phases":579,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":580,"interventions":581},[73],[471],[473,452,474,475,476,477,478,479,480,481,482,483,484,485],{"nctId":487,"briefTitle":488,"status":370,"phases":583,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":584,"interventions":585},[73],[471],[495,452,474,475,476,477,478,479,480,481,482,483,484,485,496,497],{"trials":587,"activeCount":82},[],{"trials":589,"activeCount":82},[],{"intervention":478,"totalTrials":453,"cells":591},{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":598,"PHASE4":608,"NA":610},{"trials":593,"activeCount":82},[],{"trials":595,"activeCount":82},[],{"trials":597,"activeCount":82},[],{"trials":599,"activeCount":82},[600,604],{"nctId":464,"briefTitle":465,"status":370,"phases":601,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":602,"interventions":603},[73],[471],[473,452,474,475,476,477,478,479,480,481,482,483,484,485],{"nctId":487,"briefTitle":488,"status":370,"phases":605,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":606,"interventions":607},[73],[471],[495,452,474,475,476,477,478,479,480,481,482,483,484,485,496,497],{"trials":609,"activeCount":82},[],{"trials":611,"activeCount":82},[],{"intervention":479,"totalTrials":453,"cells":613},{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":618,"PHASE3":620,"PHASE4":630,"NA":632},{"trials":615,"activeCount":82},[],{"trials":617,"activeCount":82},[],{"trials":619,"activeCount":82},[],{"trials":621,"activeCount":82},[622,626],{"nctId":464,"briefTitle":465,"status":370,"phases":623,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":624,"interventions":625},[73],[471],[473,452,474,475,476,477,478,479,480,481,482,483,484,485],{"nctId":487,"briefTitle":488,"status":370,"phases":627,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":628,"interventions":629},[73],[471],[495,452,474,475,476,477,478,479,480,481,482,483,484,485,496,497],{"trials":631,"activeCount":82},[],{"trials":633,"activeCount":82},[],{"intervention":480,"totalTrials":453,"cells":635},{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":640,"PHASE3":642,"PHASE4":652,"NA":654},{"trials":637,"activeCount":82},[],{"trials":639,"activeCount":82},[],{"trials":641,"activeCount":82},[],{"trials":643,"activeCount":82},[644,648],{"nctId":464,"briefTitle":465,"status":370,"phases":645,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":646,"interventions":647},[73],[471],[473,452,474,475,476,477,478,479,480,481,482,483,484,485],{"nctId":487,"briefTitle":488,"status":370,"phases":649,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":650,"interventions":651},[73],[471],[495,452,474,475,476,477,478,479,480,481,482,483,484,485,496,497],{"trials":653,"activeCount":82},[],{"trials":655,"activeCount":82},[],{"intervention":481,"totalTrials":453,"cells":657},{"EARLY_PHASE1":658,"PHASE1":660,"PHASE2":662,"PHASE3":664,"PHASE4":674,"NA":676},{"trials":659,"activeCount":82},[],{"trials":661,"activeCount":82},[],{"trials":663,"activeCount":82},[],{"trials":665,"activeCount":82},[666,670],{"nctId":464,"briefTitle":465,"status":370,"phases":667,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":668,"interventions":669},[73],[471],[473,452,474,475,476,477,478,479,480,481,482,483,484,485],{"nctId":487,"briefTitle":488,"status":370,"phases":671,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":672,"interventions":673},[73],[471],[495,452,474,475,476,477,478,479,480,481,482,483,484,485,496,497],{"trials":675,"activeCount":82},[],{"trials":677,"activeCount":82},[],{"intervention":482,"totalTrials":453,"cells":679},{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":696,"NA":698},{"trials":681,"activeCount":82},[],{"trials":683,"activeCount":82},[],{"trials":685,"activeCount":82},[],{"trials":687,"activeCount":82},[688,692],{"nctId":464,"briefTitle":465,"status":370,"phases":689,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":690,"interventions":691},[73],[471],[473,452,474,475,476,477,478,479,480,481,482,483,484,485],{"nctId":487,"briefTitle":488,"status":370,"phases":693,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":694,"interventions":695},[73],[471],[495,452,474,475,476,477,478,479,480,481,482,483,484,485,496,497],{"trials":697,"activeCount":82},[],{"trials":699,"activeCount":82},[],{"intervention":483,"totalTrials":453,"cells":701},{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":708,"PHASE4":718,"NA":720},{"trials":703,"activeCount":82},[],{"trials":705,"activeCount":82},[],{"trials":707,"activeCount":82},[],{"trials":709,"activeCount":82},[710,714],{"nctId":464,"briefTitle":465,"status":370,"phases":711,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":712,"interventions":713},[73],[471],[473,452,474,475,476,477,478,479,480,481,482,483,484,485],{"nctId":487,"briefTitle":488,"status":370,"phases":715,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":716,"interventions":717},[73],[471],[495,452,474,475,476,477,478,479,480,481,482,483,484,485,496,497],{"trials":719,"activeCount":82},[],{"trials":721,"activeCount":82},[],{"intervention":484,"totalTrials":453,"cells":723},{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":730,"PHASE4":740,"NA":742},{"trials":725,"activeCount":82},[],{"trials":727,"activeCount":82},[],{"trials":729,"activeCount":82},[],{"trials":731,"activeCount":82},[732,736],{"nctId":464,"briefTitle":465,"status":370,"phases":733,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":734,"interventions":735},[73],[471],[473,452,474,475,476,477,478,479,480,481,482,483,484,485],{"nctId":487,"briefTitle":488,"status":370,"phases":737,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":738,"interventions":739},[73],[471],[495,452,474,475,476,477,478,479,480,481,482,483,484,485,496,497],{"trials":741,"activeCount":82},[],{"trials":743,"activeCount":82},[],{"intervention":485,"totalTrials":453,"cells":745},{"EARLY_PHASE1":746,"PHASE1":748,"PHASE2":750,"PHASE3":752,"PHASE4":762,"NA":764},{"trials":747,"activeCount":82},[],{"trials":749,"activeCount":82},[],{"trials":751,"activeCount":82},[],{"trials":753,"activeCount":82},[754,758],{"nctId":464,"briefTitle":465,"status":370,"phases":755,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":756,"interventions":757},[73],[471],[473,452,474,475,476,477,478,479,480,481,482,483,484,485],{"nctId":487,"briefTitle":488,"status":370,"phases":759,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":760,"interventions":761},[73],[471],[495,452,474,475,476,477,478,479,480,481,482,483,484,485,496,497],{"trials":763,"activeCount":82},[],{"trials":765,"activeCount":82},[],{"intervention":473,"totalTrials":78,"cells":767},{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":772,"PHASE3":774,"PHASE4":780,"NA":782},{"trials":769,"activeCount":82},[],{"trials":771,"activeCount":82},[],{"trials":773,"activeCount":82},[],{"trials":775,"activeCount":82},[776],{"nctId":464,"briefTitle":465,"status":370,"phases":777,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":778,"interventions":779},[73],[471],[473,452,474,475,476,477,478,479,480,481,482,483,484,485],{"trials":781,"activeCount":82},[],{"trials":783,"activeCount":82},[],{"intervention":785,"totalTrials":78,"cells":786},"Fluvastatin",{"EARLY_PHASE1":787,"PHASE1":789,"PHASE2":791,"PHASE3":793,"PHASE4":805,"NA":807},{"trials":788,"activeCount":82},[],{"trials":790,"activeCount":82},[],{"trials":792,"activeCount":82},[],{"trials":794,"activeCount":82},[795],{"nctId":796,"briefTitle":797,"status":417,"phases":798,"primaryCompletion":799,"completion":800,"start":801,"enrollment":802,"conditions":803,"interventions":804},"NCT00223041","Cranoc Lipid Study in Renal Transplantation",[72,73],"2009-11","2010-12","2003-04",200,[20],[785],{"trials":806,"activeCount":82},[],{"trials":808,"activeCount":82},[],{"intervention":810,"totalTrials":78,"cells":811},"5-Fluorouracil",{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":816,"PHASE3":818,"PHASE4":837,"NA":839},{"trials":813,"activeCount":82},[],{"trials":815,"activeCount":82},[],{"trials":817,"activeCount":82},[],{"trials":819,"activeCount":82},[820],{"nctId":821,"briefTitle":822,"status":823,"phases":824,"primaryCompletion":825,"completion":37,"start":826,"enrollment":827,"conditions":828,"interventions":831},"NCT02509286","Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus","UNKNOWN",[73],"2024-05-01","2016-01",438,[829,830],"Esophageal Adenocarcinoma (UICC TNM7)","Adenocarcinoma of the Esophagogastric Junction",[810,832,833,834,835,836],"Leucovorin","Oxaliplatin","Docetaxel","Carboplatin","Paclitaxel",{"trials":838,"activeCount":82},[],{"trials":840,"activeCount":82},[],{"intervention":832,"totalTrials":78,"cells":842},{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":849,"PHASE4":855,"NA":857},{"trials":844,"activeCount":82},[],{"trials":846,"activeCount":82},[],{"trials":848,"activeCount":82},[],{"trials":850,"activeCount":82},[851],{"nctId":821,"briefTitle":822,"status":823,"phases":852,"primaryCompletion":825,"completion":37,"start":826,"enrollment":827,"conditions":853,"interventions":854},[73],[829,830],[810,832,833,834,835,836],{"trials":856,"activeCount":82},[],{"trials":858,"activeCount":82},[],{"intervention":833,"totalTrials":78,"cells":860},{"EARLY_PHASE1":861,"PHASE1":863,"PHASE2":865,"PHASE3":867,"PHASE4":873,"NA":875},{"trials":862,"activeCount":82},[],{"trials":864,"activeCount":82},[],{"trials":866,"activeCount":82},[],{"trials":868,"activeCount":82},[869],{"nctId":821,"briefTitle":822,"status":823,"phases":870,"primaryCompletion":825,"completion":37,"start":826,"enrollment":827,"conditions":871,"interventions":872},[73],[829,830],[810,832,833,834,835,836],{"trials":874,"activeCount":82},[],{"trials":876,"activeCount":82},[],{"intervention":834,"totalTrials":78,"cells":878},{"EARLY_PHASE1":879,"PHASE1":881,"PHASE2":883,"PHASE3":885,"PHASE4":891,"NA":893},{"trials":880,"activeCount":82},[],{"trials":882,"activeCount":82},[],{"trials":884,"activeCount":82},[],{"trials":886,"activeCount":82},[887],{"nctId":821,"briefTitle":822,"status":823,"phases":888,"primaryCompletion":825,"completion":37,"start":826,"enrollment":827,"conditions":889,"interventions":890},[73],[829,830],[810,832,833,834,835,836],{"trials":892,"activeCount":82},[],{"trials":894,"activeCount":82},[],{"intervention":835,"totalTrials":78,"cells":896},{"EARLY_PHASE1":897,"PHASE1":899,"PHASE2":901,"PHASE3":903,"PHASE4":909,"NA":911},{"trials":898,"activeCount":82},[],{"trials":900,"activeCount":82},[],{"trials":902,"activeCount":82},[],{"trials":904,"activeCount":82},[905],{"nctId":821,"briefTitle":822,"status":823,"phases":906,"primaryCompletion":825,"completion":37,"start":826,"enrollment":827,"conditions":907,"interventions":908},[73],[829,830],[810,832,833,834,835,836],{"trials":910,"activeCount":82},[],{"trials":912,"activeCount":82},[],{"intervention":836,"totalTrials":78,"cells":914},{"EARLY_PHASE1":915,"PHASE1":917,"PHASE2":919,"PHASE3":921,"PHASE4":927,"NA":929},{"trials":916,"activeCount":82},[],{"trials":918,"activeCount":82},[],{"trials":920,"activeCount":82},[],{"trials":922,"activeCount":82},[923],{"nctId":821,"briefTitle":822,"status":823,"phases":924,"primaryCompletion":825,"completion":37,"start":826,"enrollment":827,"conditions":925,"interventions":926},[73],[829,830],[810,832,833,834,835,836],{"trials":928,"activeCount":82},[],{"trials":930,"activeCount":82},[],{"intervention":495,"totalTrials":78,"cells":932},{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":937,"PHASE3":939,"PHASE4":945,"NA":947},{"trials":934,"activeCount":82},[],{"trials":936,"activeCount":82},[],{"trials":938,"activeCount":82},[],{"trials":940,"activeCount":82},[941],{"nctId":487,"briefTitle":488,"status":370,"phases":942,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":943,"interventions":944},[73],[471],[495,452,474,475,476,477,478,479,480,481,482,483,484,485,496,497],{"trials":946,"activeCount":82},[],{"trials":948,"activeCount":82},[],{"intervention":496,"totalTrials":78,"cells":950},{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":957,"PHASE4":963,"NA":965},{"trials":952,"activeCount":82},[],{"trials":954,"activeCount":82},[],{"trials":956,"activeCount":82},[],{"trials":958,"activeCount":82},[959],{"nctId":487,"briefTitle":488,"status":370,"phases":960,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":961,"interventions":962},[73],[471],[495,452,474,475,476,477,478,479,480,481,482,483,484,485,496,497],{"trials":964,"activeCount":82},[],{"trials":966,"activeCount":82},[],{"intervention":497,"totalTrials":78,"cells":968},{"EARLY_PHASE1":969,"PHASE1":971,"PHASE2":973,"PHASE3":975,"PHASE4":981,"NA":983},{"trials":970,"activeCount":82},[],{"trials":972,"activeCount":82},[],{"trials":974,"activeCount":82},[],{"trials":976,"activeCount":82},[977],{"nctId":487,"briefTitle":488,"status":370,"phases":978,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":979,"interventions":980},[73],[471],[495,452,474,475,476,477,478,479,480,481,482,483,484,485,496,497],{"trials":982,"activeCount":82},[],{"trials":984,"activeCount":82},[],{"intervention":986,"totalTrials":78,"cells":987},"pemetrexed + paclitaxel",{"EARLY_PHASE1":988,"PHASE1":990,"PHASE2":992,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":989,"activeCount":82},[],{"trials":991,"activeCount":82},[],{"trials":993,"activeCount":82},[994],{"nctId":995,"briefTitle":996,"status":823,"phases":997,"primaryCompletion":998,"completion":419,"start":999,"enrollment":1000,"conditions":1001,"interventions":1003},"NCT00786552","Pemetrexed + Paclitaxel in Patients With Recurrent\u002FAdvanced Thyroid Cancer",[72],"2012-11","2008-11",47,[1002],"Thyroid Cancer",[986],{"trials":1005,"activeCount":82},[],{"trials":1007,"activeCount":82},[],{"trials":1009,"activeCount":82},[],{"intervention":1011,"totalTrials":78,"cells":1012},"Cetuximab",{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1017,"PHASE3":1030,"PHASE4":1032,"NA":1034},{"trials":1014,"activeCount":82},[],{"trials":1016,"activeCount":82},[],{"trials":1018,"activeCount":82},[1019],{"nctId":1020,"briefTitle":1021,"status":370,"phases":1022,"primaryCompletion":1023,"completion":1023,"start":1024,"enrollment":1025,"conditions":1026,"interventions":1028},"NCT01787006","Definitive Radiochemotherapy Plus\u002FMinus Cetuximab in Unresectable Locally Advanced Esophageal Cancer",[72],"2018-09-06","2011-09",74,[1027],"Esophageal Cancer",[1011,1029],"Cisplatin, 5-FU",{"trials":1031,"activeCount":82},[],{"trials":1033,"activeCount":82},[],{"trials":1035,"activeCount":82},[],{"intervention":1029,"totalTrials":78,"cells":1037},{"EARLY_PHASE1":1038,"PHASE1":1040,"PHASE2":1042,"PHASE3":1048,"PHASE4":1050,"NA":1052},{"trials":1039,"activeCount":82},[],{"trials":1041,"activeCount":82},[],{"trials":1043,"activeCount":82},[1044],{"nctId":1020,"briefTitle":1021,"status":370,"phases":1045,"primaryCompletion":1023,"completion":1023,"start":1024,"enrollment":1025,"conditions":1046,"interventions":1047},[72],[1027],[1011,1029],{"trials":1049,"activeCount":82},[],{"trials":1051,"activeCount":82},[],{"trials":1053,"activeCount":82},[],{"intervention":1055,"totalTrials":78,"cells":1056},"Sorafenib",{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1074,"PHASE4":1076,"NA":1078},{"trials":1058,"activeCount":82},[],{"trials":1060,"activeCount":82},[],{"trials":1062,"activeCount":82},[1063],{"nctId":1064,"briefTitle":1065,"status":370,"phases":1066,"primaryCompletion":1067,"start":1068,"enrollment":1069,"conditions":1070,"interventions":1072},"NCT00623402","Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma",[72],"2009-10","2008-01",55,[1071],"Melanoma",[1055,1073],"pegylated interferon α-2b",{"trials":1075,"activeCount":82},[],{"trials":1077,"activeCount":82},[],{"trials":1079,"activeCount":82},[],{"intervention":1073,"totalTrials":78,"cells":1081},{"EARLY_PHASE1":1082,"PHASE1":1084,"PHASE2":1086,"PHASE3":1092,"PHASE4":1094,"NA":1096},{"trials":1083,"activeCount":82},[],{"trials":1085,"activeCount":82},[],{"trials":1087,"activeCount":82},[1088],{"nctId":1064,"briefTitle":1065,"status":370,"phases":1089,"primaryCompletion":1067,"start":1068,"enrollment":1069,"conditions":1090,"interventions":1091},[72],[1071],[1055,1073],{"trials":1093,"activeCount":82},[],{"trials":1095,"activeCount":82},[],{"trials":1097,"activeCount":82},[],{"intervention":1099,"totalTrials":78,"cells":1100},"Adriamycin",{"EARLY_PHASE1":1101,"PHASE1":1103,"PHASE2":1105,"PHASE3":1118,"PHASE4":1120,"NA":1122},{"trials":1102,"activeCount":82},[],{"trials":1104,"activeCount":82},[],{"trials":1106,"activeCount":82},[1107],{"nctId":1108,"briefTitle":1109,"status":823,"phases":1110,"primaryCompletion":1111,"completion":1111,"start":1112,"enrollment":1113,"conditions":1114,"interventions":1116},"NCT00204568","Trofosfamide Versus Adriamycin in Elderly Patients With Soft Tissue Sarcoma (STS)",[72],"2013-10","2004-08",117,[1115],"Sarcoma, Soft Tissue",[1099,1117],"Trofosfamide",{"trials":1119,"activeCount":82},[],{"trials":1121,"activeCount":82},[],{"trials":1123,"activeCount":82},[],{"intervention":1117,"totalTrials":78,"cells":1125},{"EARLY_PHASE1":1126,"PHASE1":1128,"PHASE2":1130,"PHASE3":1136,"PHASE4":1138,"NA":1140},{"trials":1127,"activeCount":82},[],{"trials":1129,"activeCount":82},[],{"trials":1131,"activeCount":82},[1132],{"nctId":1108,"briefTitle":1109,"status":823,"phases":1133,"primaryCompletion":1111,"completion":1111,"start":1112,"enrollment":1113,"conditions":1134,"interventions":1135},[72],[1115],[1099,1117],{"trials":1137,"activeCount":82},[],{"trials":1139,"activeCount":82},[],{"trials":1141,"activeCount":82},[],{"intervention":1143,"totalTrials":78,"cells":1144},"mepolizumab",{"EARLY_PHASE1":1145,"PHASE1":1147,"PHASE2":1149,"PHASE3":1161,"PHASE4":1163,"NA":1165},{"trials":1146,"activeCount":82},[],{"trials":1148,"activeCount":82},[],{"trials":1150,"activeCount":82},[1151],{"nctId":1152,"briefTitle":1153,"status":370,"phases":1154,"primaryCompletion":1155,"start":1156,"enrollment":1157,"conditions":1158,"interventions":1160},"NCT00716651","Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome",[72],"2010-07","2008-07",10,[1159],"Churg Strauss Syndrome",[1143],{"trials":1162,"activeCount":82},[],{"trials":1164,"activeCount":82},[],{"trials":1166,"activeCount":82},[],{"intervention":1168,"totalTrials":453,"cells":1169},"TAIZ",{"EARLY_PHASE1":1170,"PHASE1":1172,"PHASE2":1190,"PHASE3":1192,"PHASE4":1194,"NA":1196},{"trials":1171,"activeCount":82},[],{"trials":1173,"activeCount":82},[1174,1182],{"nctId":1175,"briefTitle":1176,"status":823,"phases":1177,"completion":1178,"start":1179,"enrollment":1157,"conditions":1180,"interventions":1181},"NCT00223093","TAIZ -Monocytes for the Induction of Donor Specific Tolerance in Renal Allograft Recipients (Cadaver Kidney)",[71],"2005-08","2004-02",[20],[1168],{"nctId":1183,"briefTitle":1184,"status":823,"phases":1185,"completion":1186,"start":1187,"enrollment":1157,"conditions":1188,"interventions":1189},"NCT00223067","Induction of Donor-Specific Tolerance in Renal Allograft Recipients (Living Donor) With TAIZ-Monocytes",[71],"2006-05","2005-03",[20],[1168],{"trials":1191,"activeCount":82},[],{"trials":1193,"activeCount":82},[],{"trials":1195,"activeCount":82},[],{"trials":1197,"activeCount":82},[],{"intervention":1199,"totalTrials":78,"cells":1200},"Tapentadol immediate release",{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1215,"PHASE3":1217,"PHASE4":1219,"NA":1221},{"trials":1202,"activeCount":82},[],{"trials":1204,"activeCount":82},[1205],{"nctId":1206,"briefTitle":1207,"status":417,"phases":1208,"primaryCompletion":1209,"completion":1209,"start":1210,"enrollment":8,"conditions":1211,"interventions":1214},"NCT01615510","Evaluation of the Antihyperalgesic Effect of Tapentadol in Two Human Experimental Models",[71],"2013-03","2012-10",[17,1212,1213],"Hyperalgesia","Allodynia",[1199],{"trials":1216,"activeCount":82},[],{"trials":1218,"activeCount":82},[],{"trials":1220,"activeCount":82},[],{"trials":1222,"activeCount":82},[],{"intervention":1224,"totalTrials":78,"cells":1225},"controlled-ileocolonic-release nicotinamide",{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1242,"PHASE3":1244,"PHASE4":1246,"NA":1248},{"trials":1227,"activeCount":82},[],{"trials":1229,"activeCount":82},[1230],{"nctId":1231,"briefTitle":1232,"status":370,"phases":1233,"primaryCompletion":1234,"completion":1234,"start":1235,"enrollment":1236,"conditions":1237,"interventions":1240},"NCT05258474","Safety and Pharmacokinetics of Oral Controlled-ileocolonic-release Nicotinamide (CICR-NAM)",[71],"2022-03-30","2020-12-04",49,[1238,1239],"Safety Issues","Pharmacokinetic",[1224,1241],"Immediate-release nicotinamide",{"trials":1243,"activeCount":82},[],{"trials":1245,"activeCount":82},[],{"trials":1247,"activeCount":82},[],{"trials":1249,"activeCount":82},[],{"intervention":1241,"totalTrials":78,"cells":1251},{"EARLY_PHASE1":1252,"PHASE1":1254,"PHASE2":1260,"PHASE3":1262,"PHASE4":1264,"NA":1266},{"trials":1253,"activeCount":82},[],{"trials":1255,"activeCount":82},[1256],{"nctId":1231,"briefTitle":1232,"status":370,"phases":1257,"primaryCompletion":1234,"completion":1234,"start":1235,"enrollment":1236,"conditions":1258,"interventions":1259},[71],[1238,1239],[1224,1241],{"trials":1261,"activeCount":82},[],{"trials":1263,"activeCount":82},[],{"trials":1265,"activeCount":82},[],{"trials":1267,"activeCount":82},[],{"intervention":1269,"totalTrials":78,"cells":1270},"controlled-ileal-release nicotinic acid",{"EARLY_PHASE1":1271,"PHASE1":1273,"PHASE2":1285,"PHASE3":1287,"PHASE4":1289,"NA":1291},{"trials":1272,"activeCount":82},[],{"trials":1274,"activeCount":82},[1275],{"nctId":1276,"briefTitle":1277,"status":370,"phases":1278,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":1282,"interventions":1283},"NCT06378125","Evaluation of Safety and Pharmacokinetics of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) Compared to Immediate-release Nicotinic Acid and Placebo in Healthy Subjects and Subjects With Prediabetes",[71],"2024-11-12","2022-12-19",60,[1238,1239],[1269,1284],"immediate-release nicotinic acid",{"trials":1286,"activeCount":82},[],{"trials":1288,"activeCount":82},[],{"trials":1290,"activeCount":82},[],{"trials":1292,"activeCount":82},[],{"intervention":1284,"totalTrials":78,"cells":1294},{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1303,"PHASE3":1305,"PHASE4":1307,"NA":1309},{"trials":1296,"activeCount":82},[],{"trials":1298,"activeCount":82},[1299],{"nctId":1276,"briefTitle":1277,"status":370,"phases":1300,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":1301,"interventions":1302},[71],[1238,1239],[1269,1284],{"trials":1304,"activeCount":82},[],{"trials":1306,"activeCount":82},[],{"trials":1308,"activeCount":82},[],{"trials":1310,"activeCount":82},[],{"intervention":1312,"totalTrials":78,"cells":1313},"Propofol",{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1318,"PHASE3":1320,"PHASE4":1322,"NA":1324},{"trials":1315,"activeCount":82},[],{"trials":1317,"activeCount":82},[],{"trials":1319,"activeCount":82},[],{"trials":1321,"activeCount":82},[],{"trials":1323,"activeCount":82},[],{"trials":1325,"activeCount":82},[1326],{"nctId":1327,"briefTitle":1328,"status":370,"phases":1329,"primaryCompletion":1330,"completion":1330,"start":1331,"enrollment":1332,"conditions":1333,"interventions":1335},"NCT01293266","Effect of Propofol and Sevoflurane on Lactate During Anesthesia for Pediatric Heart Catheterisation",[75],"2010-08","2009-06",40,[1334],"Metabolic Acidosis",[1312],{"intervention":1337,"totalTrials":78,"cells":1338},"administration of sufentanil",{"EARLY_PHASE1":1339,"PHASE1":1341,"PHASE2":1343,"PHASE3":1345,"PHASE4":1347,"NA":1349},{"trials":1340,"activeCount":82},[],{"trials":1342,"activeCount":82},[],{"trials":1344,"activeCount":82},[],{"trials":1346,"activeCount":82},[],{"trials":1348,"activeCount":82},[],{"trials":1350,"activeCount":82},[1351],{"nctId":1352,"briefTitle":1353,"status":370,"phases":1354,"primaryCompletion":1355,"completion":420,"start":1356,"enrollment":1357,"conditions":1358,"interventions":1360},"NCT01525537","Surgical Pleth Index (SPI) Guided Analgesia During Sevoflurane Anesthesia",[75],"2010-02","2009-03",82,[1359],"Balanced Anesthesia",[1337,1361],"sufentanil",{"intervention":1361,"totalTrials":78,"cells":1363},{"EARLY_PHASE1":1364,"PHASE1":1366,"PHASE2":1368,"PHASE3":1370,"PHASE4":1372,"NA":1374},{"trials":1365,"activeCount":82},[],{"trials":1367,"activeCount":82},[],{"trials":1369,"activeCount":82},[],{"trials":1371,"activeCount":82},[],{"trials":1373,"activeCount":82},[],{"trials":1375,"activeCount":82},[1376],{"nctId":1352,"briefTitle":1353,"status":370,"phases":1377,"primaryCompletion":1355,"completion":420,"start":1356,"enrollment":1357,"conditions":1378,"interventions":1379},[75],[1359],[1337,1361],{"intervention":1381,"totalTrials":78,"cells":1382},"midazolam",{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1387,"PHASE3":1389,"PHASE4":1391,"NA":1393},{"trials":1384,"activeCount":82},[],{"trials":1386,"activeCount":82},[],{"trials":1388,"activeCount":82},[],{"trials":1390,"activeCount":82},[],{"trials":1392,"activeCount":82},[],{"trials":1394,"activeCount":82},[1395],{"nctId":1396,"briefTitle":1397,"status":370,"phases":1398,"primaryCompletion":1399,"completion":1399,"start":1178,"enrollment":1281,"conditions":1400,"interventions":1402},"NCT00638729","Clonidine Versus Midazolam for Premedication",[75],"2007-03",[1401,17],"Anxiety",[1381,1403],"clonidine",{"intervention":1403,"totalTrials":78,"cells":1405},{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1412,"PHASE4":1414,"NA":1416},{"trials":1407,"activeCount":82},[],{"trials":1409,"activeCount":82},[],{"trials":1411,"activeCount":82},[],{"trials":1413,"activeCount":82},[],{"trials":1415,"activeCount":82},[],{"trials":1417,"activeCount":82},[1418],{"nctId":1396,"briefTitle":1397,"status":370,"phases":1419,"primaryCompletion":1399,"completion":1399,"start":1178,"enrollment":1281,"conditions":1420,"interventions":1421},[75],[1401,17],[1381,1403],{"intervention":1423,"totalTrials":78,"cells":1424},"Ovarian stimulation in a GnRH-antagonist protocol",{"EARLY_PHASE1":1425,"PHASE1":1427,"PHASE2":1429,"PHASE3":1431,"PHASE4":1433,"NA":1435},{"trials":1426,"activeCount":82},[],{"trials":1428,"activeCount":82},[],{"trials":1430,"activeCount":82},[],{"trials":1432,"activeCount":82},[],{"trials":1434,"activeCount":82},[],{"trials":1436,"activeCount":82},[1437],{"nctId":1438,"briefTitle":1439,"status":370,"phases":1440,"primaryCompletion":1441,"completion":1442,"start":1443,"enrollment":1444,"conditions":1445,"interventions":1447},"NCT01206803","Ovarian Response Prediction in In Vitro Fertilization (IVF) Patients",[],"2013-12","2014-01","2010-09",294,[1446],"Infertility, Subfertility",[1423],{"intervention":1449,"totalTrials":78,"cells":1450},"Dobutamine",{"EARLY_PHASE1":1451,"PHASE1":1453,"PHASE2":1455,"PHASE3":1457,"PHASE4":1459,"NA":1461},{"trials":1452,"activeCount":82},[],{"trials":1454,"activeCount":82},[],{"trials":1456,"activeCount":82},[],{"trials":1458,"activeCount":82},[],{"trials":1460,"activeCount":82},[],{"trials":1462,"activeCount":82},[1463],{"nctId":1464,"briefTitle":1465,"status":370,"phases":1466,"primaryCompletion":1467,"completion":1467,"start":1468,"enrollment":1469,"conditions":1470,"interventions":1473},"NCT02559141","Non-invasive Early Goal Directed Therapy in Colorectal Surgery: a Feasibility Study",[75],"2015-10","2014-03",80,[1471,1472],"Perioperative\u002FPostoperative Complications","C.Surgical Procedure; Digestive System",[1449],{"intervention":1475,"totalTrials":78,"cells":1476},"Stress",{"EARLY_PHASE1":1477,"PHASE1":1479,"PHASE2":1481,"PHASE3":1483,"PHASE4":1485,"NA":1487},{"trials":1478,"activeCount":82},[],{"trials":1480,"activeCount":82},[],{"trials":1482,"activeCount":82},[],{"trials":1484,"activeCount":82},[],{"trials":1486,"activeCount":82},[],{"trials":1488,"activeCount":82},[1489],{"nctId":1490,"briefTitle":1491,"status":1492,"phases":1493,"primaryCompletion":1494,"completion":1495,"start":1496,"enrollment":82,"conditions":1497,"interventions":1499},"NCT02316132","Confocal Laser Endomicroscopy, IBS and Stress","WITHDRAWN",[75],"2016-06","2016-07","2014-12",[1498],"Irritable Bowel Syndrome",[1475,1500],"Control",{"intervention":1500,"totalTrials":78,"cells":1502},{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1507,"PHASE3":1509,"PHASE4":1511,"NA":1513},{"trials":1504,"activeCount":82},[],{"trials":1506,"activeCount":82},[],{"trials":1508,"activeCount":82},[],{"trials":1510,"activeCount":82},[],{"trials":1512,"activeCount":82},[],{"trials":1514,"activeCount":82},[1515],{"nctId":1490,"briefTitle":1491,"status":1492,"phases":1516,"primaryCompletion":1494,"completion":1495,"start":1496,"enrollment":82,"conditions":1517,"interventions":1518},[75],[1498],[1475,1500],{"intervention":1520,"totalTrials":78,"cells":1521},"lithium",{"EARLY_PHASE1":1522,"PHASE1":1524,"PHASE2":1526,"PHASE3":1528,"PHASE4":1530,"NA":1532},{"trials":1523,"activeCount":82},[],{"trials":1525,"activeCount":82},[],{"trials":1527,"activeCount":82},[],{"trials":1529,"activeCount":82},[],{"trials":1531,"activeCount":82},[],{"trials":1533,"activeCount":82},[1534],{"nctId":1535,"briefTitle":1536,"status":417,"phases":1537,"completion":1538,"start":1539,"enrollment":1540,"conditions":1541,"interventions":1544},"NCT00520026","Suicide Prevention by Lithium - the Lithium Intervention Study",[75],"2006-06","2001-01",167,[1542,1543],"Suicide","Depressive Disorders",[1520],{"intervention":1546,"totalTrials":78,"cells":1547},"Silicone gel",{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1554,"PHASE4":1556,"NA":1558},{"trials":1549,"activeCount":82},[],{"trials":1551,"activeCount":82},[],{"trials":1553,"activeCount":82},[],{"trials":1555,"activeCount":82},[],{"trials":1557,"activeCount":82},[],{"trials":1559,"activeCount":82},[1560],{"nctId":1561,"briefTitle":1562,"status":823,"phases":1563,"completion":1564,"start":1565,"enrollment":1566,"conditions":1567,"interventions":1570},"NCT00565552","Influence of a Silicone Gel (Dermatix®) on Thoracic Scar Formation After Harvesting of Autologous Rib Cartilage",[75],"2009-01","2007-01",20,[1568,1569],"Cicatrix, Hypertrophic","Keloid",[1546],{"intervention":1572,"totalTrials":78,"cells":1573},"Lacosamide 10mg\u002Fml",{"EARLY_PHASE1":1574,"PHASE1":1576,"PHASE2":1578,"PHASE3":1580,"PHASE4":1582,"NA":1584},{"trials":1575,"activeCount":82},[],{"trials":1577,"activeCount":82},[],{"trials":1579,"activeCount":82},[],{"trials":1581,"activeCount":82},[],{"trials":1583,"activeCount":82},[],{"trials":1585,"activeCount":82},[1586],{"nctId":1587,"briefTitle":1588,"status":370,"phases":1589,"primaryCompletion":419,"completion":419,"start":1590,"enrollment":1591,"conditions":1592,"interventions":1594},"NCT01620840","Lacosamid-i.v.-Register",[],"2011-06",130,[1593],"Epilepsy With Partial Onset Seizures With or Without Secondary Generalization",[1572],{"intervention":1596,"totalTrials":78,"cells":1597},"tacrolimus",{"EARLY_PHASE1":1598,"PHASE1":1600,"PHASE2":1602,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1599,"activeCount":82},[],{"trials":1601,"activeCount":82},[],{"trials":1603,"activeCount":82},[],{"trials":1605,"activeCount":82},[],{"trials":1607,"activeCount":82},[],{"trials":1609,"activeCount":82},[1610],{"nctId":1611,"briefTitle":1612,"status":370,"phases":1613,"primaryCompletion":1538,"completion":1614,"start":1187,"enrollment":802,"conditions":1615,"interventions":1617},"NCT00223054","Polymorphism of the Cytochrome P450-system in Renal Transplants",[],"2006-10",[1616],"Function of Renal Transplant",[1596,1618,1619,1620],"sirolimus","everolimus","cyclosporin A",{"intervention":1618,"totalTrials":78,"cells":1622},{"EARLY_PHASE1":1623,"PHASE1":1625,"PHASE2":1627,"PHASE3":1629,"PHASE4":1631,"NA":1633},{"trials":1624,"activeCount":82},[],{"trials":1626,"activeCount":82},[],{"trials":1628,"activeCount":82},[],{"trials":1630,"activeCount":82},[],{"trials":1632,"activeCount":82},[],{"trials":1634,"activeCount":82},[1635],{"nctId":1611,"briefTitle":1612,"status":370,"phases":1636,"primaryCompletion":1538,"completion":1614,"start":1187,"enrollment":802,"conditions":1637,"interventions":1638},[],[1616],[1596,1618,1619,1620],{"intervention":1619,"totalTrials":78,"cells":1640},{"EARLY_PHASE1":1641,"PHASE1":1643,"PHASE2":1645,"PHASE3":1647,"PHASE4":1649,"NA":1651},{"trials":1642,"activeCount":82},[],{"trials":1644,"activeCount":82},[],{"trials":1646,"activeCount":82},[],{"trials":1648,"activeCount":82},[],{"trials":1650,"activeCount":82},[],{"trials":1652,"activeCount":82},[1653],{"nctId":1611,"briefTitle":1612,"status":370,"phases":1654,"primaryCompletion":1538,"completion":1614,"start":1187,"enrollment":802,"conditions":1655,"interventions":1656},[],[1616],[1596,1618,1619,1620],{"intervention":1620,"totalTrials":78,"cells":1658},{"EARLY_PHASE1":1659,"PHASE1":1661,"PHASE2":1663,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1660,"activeCount":82},[],{"trials":1662,"activeCount":82},[],{"trials":1664,"activeCount":82},[],{"trials":1666,"activeCount":82},[],{"trials":1668,"activeCount":82},[],{"trials":1670,"activeCount":82},[1671],{"nctId":1611,"briefTitle":1612,"status":370,"phases":1672,"primaryCompletion":1538,"completion":1614,"start":1187,"enrollment":802,"conditions":1673,"interventions":1674},[],[1616],[1596,1618,1619,1620],{"intervention":1676,"totalTrials":78,"cells":1677},"Infliximab",{"EARLY_PHASE1":1678,"PHASE1":1680,"PHASE2":1682,"PHASE3":1684,"PHASE4":1686,"NA":1688},{"trials":1679,"activeCount":82},[],{"trials":1681,"activeCount":82},[],{"trials":1683,"activeCount":82},[],{"trials":1685,"activeCount":82},[],{"trials":1687,"activeCount":82},[],{"trials":1689,"activeCount":82},[1690],{"nctId":1691,"briefTitle":1692,"status":370,"phases":1693,"primaryCompletion":1694,"completion":1695,"start":1696,"enrollment":1697,"conditions":1698,"interventions":1700},"NCT02694588","Clinical and Molecular Phenotyping in IBD",[75],"2018-10","2021-12","2014-06",90,[1699],"IBD",[1676,1701],"Vedolizumab",{"intervention":1701,"totalTrials":78,"cells":1703},{"EARLY_PHASE1":1704,"PHASE1":1706,"PHASE2":1708,"PHASE3":1710,"PHASE4":1712,"NA":1714},{"trials":1705,"activeCount":82},[],{"trials":1707,"activeCount":82},[],{"trials":1709,"activeCount":82},[],{"trials":1711,"activeCount":82},[],{"trials":1713,"activeCount":82},[],{"trials":1715,"activeCount":82},[1716],{"nctId":1691,"briefTitle":1692,"status":370,"phases":1717,"primaryCompletion":1694,"completion":1695,"start":1696,"enrollment":1697,"conditions":1718,"interventions":1719},[75],[1699],[1676,1701],{"intervention":1721,"totalTrials":78,"cells":1722},"i.v. beta-blocker",{"EARLY_PHASE1":1723,"PHASE1":1725,"PHASE2":1727,"PHASE3":1729,"PHASE4":1731,"NA":1733},{"trials":1724,"activeCount":82},[],{"trials":1726,"activeCount":82},[],{"trials":1728,"activeCount":82},[],{"trials":1730,"activeCount":82},[],{"trials":1732,"activeCount":82},[],{"trials":1734,"activeCount":82},[1735],{"nctId":1736,"briefTitle":1737,"status":370,"phases":1738,"primaryCompletion":1356,"completion":799,"start":1739,"enrollment":1740,"conditions":1741,"interventions":1745},"NCT00700466","Intravenous Beta-blockade for Improvement of Autonomic Activity",[],"2008-03",100,[1742,1743,1744],"Hypertension","Tachycardia","Heart Rate Variability",[1721],{"intervention":1747,"totalTrials":78,"cells":1748},"cafedrine\u002Ftheodrenaline, urapidil",{"EARLY_PHASE1":1749,"PHASE1":1751,"PHASE2":1753,"PHASE3":1755,"PHASE4":1757,"NA":1759},{"trials":1750,"activeCount":82},[],{"trials":1752,"activeCount":82},[],{"trials":1754,"activeCount":82},[],{"trials":1756,"activeCount":82},[],{"trials":1758,"activeCount":82},[],{"trials":1760,"activeCount":82},[1761],{"nctId":1762,"briefTitle":1763,"status":1492,"phases":1764,"enrollment":82,"conditions":1765,"interventions":1767},"NCT01311414","Effect of Cafedrine\u002FTheodrenaline and Urapidil on Cerebral Oxygenation",[75],[1766],"Cerebral Ischemia",[1747]]